The Prism Conformity Trial for Post-Traumatic Stress Disorder in Adolescents

Inclusion Criteria

• Ages 12 to 21 years.
• Any gender.
• Diagnosis of PTSD, established according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V).
• ≥1 year since index trauma.
• For candidate participants under 18 years old: Willingness and ability to provide assent, with the participant's legal guardian able and willing to provide informed consent for their study participation.
• For candidate participants 18 years old and above: Willingness and ability to provide informed consent for their study participation.
• English speaking, writing and reading.
• Normal or corrected-to-normal vision and hearing.

Exclusion Criteria

• Have completed one or more full courses of trauma-focused therapy in the past (i.e., Eye Movement Desensitization and Reprocessing [EMDR], Prolong Exposure Therapy etc.), eligibility will be deemed upon the clinical judgement of the investigator.
• Diagnosis for schizophrenia, schizoaffective disorder, schizophreniform disorder, Bipolar I disorder, or delusional disorder.
• Any mood or anxiety disorder as defined by the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5), that has been the primary focus of mental health treatment within the 6 months prior to screening, based on the clinical judgment of the site investigator.
• Diagnosis of autism spectrum requiring substantial support, intellectual disability of mild severity at discretion of investigator.
• Diagnosis of moderate or severe substance use disorder within the last 3 months of the screening visit (as defined in DSM-5-substance use disorder) or at the screening visit.
• Current symptom level of moderate or severe ADHD (as defined in DSM-5 ADHD disorder) or at screening visit.
• Any change in- or initiation of- psychotropic medications within the past 4 weeks. At the time of recruitment, subjects must have no intention of changing their medication or psychotherapy during the study duration.
• Any suicidal behavior within the past 1 year (i.e., actual attempt, interrupted attempt, aborted attempt, or preparatory acts or behavior), prior to screening and during the screening period.
• Recent initiation (within the past 3 months) of cognitive-behavioral therapy or any evidence-based PTSD psychotherapy (Cognitive Processing Therapy [CPT], Prolonged Exposure [PE], Eye Movement Desensitization and Reprocessing [EMDR]). However, continuation of established maintenance supportive therapy will be permitted.
• Any history of brain surgery, of penetrating, neurovascular, infectious, or other major brain injury, of epilepsy, or of other major neurological abnormality (including a history of traumatic brain injury [TBI] with loss of consciousness for more than 24 hours or posttraumatic amnesia for more than 7 days).
• Any unstable medical condition, as per the clinical judgement of the investigator.
• Enrollment in another interventional clinical study at screening or within 2 months prior to screening or intended enrollment within the duration of this study.
• Female subjects who are pregnant, nursing, or who plan to become pregnant while in the trial.